Heart failure, oxidative stress and allopurinol

https://doi.org/10.4081/monaldi.2005.609

Authors

  • Paolo Biagi | villabercio@tiscali.it Unità Funzionale di Medicina Interna, Ospedali Riuniti della Val di Chiana Senese, Montepulciano (SI), Italy.
  • Luigi Abate Unità Funzionale di Medicina Interna, Ospedali Riuniti della Val di Chiana Senese, Montepulciano (SI), Italy.

Abstract

Oxidative stress is one of the new and most intriguing pathogenetic hypotheses of heart failure; it involves various mechanisms such as endothelial dysfunction, mechanoenergetic uncoupling and apoptosis. Xanthine oxidase, a key enzyme in purine catabolism, is overexpressed in patients with heart failure, and it is also an important source of oxidizing activity molecules (free radicals, superoxide anion, oxygen peroxide, etc…). Allopurinol competitively inhibits the action of xanthine oxidase and effectively counters oxidative stress. It could thus prove useful in the treatment of heart failure: in fact it is the only drug that has been proven able to lower O2 consumption of dysfunctioning myocardium. The Authors briefly review the xanthine oxido-reductase enzyme system and in particular analyse the latest evidence reported in the literature on allopurinol in the treatment of heart failure.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Downloads

Published
2005-03-30
Info
Issue
Section
Reviews
Keywords:
heart failure, uric acid, oxidative stress, allopurinol
Statistics
  • Abstract views: 365

  • PDF: 249
How to Cite
Biagi, Paolo, and Luigi Abate. 2005. “Heart Failure, Oxidative Stress and Allopurinol”. Monaldi Archives for Chest Disease 64 (1). https://doi.org/10.4081/monaldi.2005.609.